07:30 AM EDT, 05/15/2024 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time treatment for patients with Stargardt disease.

To date, six patients with the retinal degenerating genetic eye disorder have been dosed in unilateral subretinal administration of the therapy candidate's phase 1/2 clinical trial, the company said. An additional three patients will be dosed in the high-dose phase.

A data and safety monitoring board is to convene next month to review the 4-week safety data from the medium dosing group before proceeding with the high dose -- the final dose in the early-stage dose-escalation safety and efficacy study, Ocugen ( OCGN ) said.

The company said it expects to provide a clinical trial update for the therapy in Q3.

Price: 1.7600, Change: +0.06, Percent Change: +3.53